Robert Gut sold $270k of QURE
director at uniQure N.V.. 10,278 shares at an average of $26.32, traded Jun 10, 2026, filed Jun 12, 2026.
Score components
- +15RoleDirector
- +13Trade size$270k at market
- +10Share of holdings soldSold 29% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000904454-26-000350, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | MOption exercise Ordinary Shares10b5-1 | +2,645 | $16.04 | $42k | 34,987 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -2,645 | $26.07 | $69k | 32,342 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -3,127 | $26.03 | $81k | 29,215 | Jun 12, 2026 |
| Jun 10, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -1,780 | $26.05 | $46k | 27,435 | Jun 12, 2026 |
| Jun 10, 2026 | AGrant or award Ordinary Shares10b5-1 | +7,550 | $0.00 | $0 | 34,985 | Jun 12, 2026 |
| Jun 11, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -2,726 | $27.06 | $74k | 32,259 | Jun 12, 2026 |
| Jun 10, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,645 | $0.00 | $0 | 0 | Jun 12, 2026 |
| Jun 10, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +13,980 | $0.00 | $0 | 13,980 | Jun 12, 2026 |
Related signals
Other insiders at uniQure N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | uniQure N.V. | Matthew C Kapusta CEO, Managing Director | $952k 21,082 shares | -4% | |
| 25Weak | uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $1.4M 30,000 shares | -17% | |
| 40Moderate | uniQure N.V. | Jack Kaye director | $983k 21,167 shares | -70% | |
| 38Weak | uniQure N.V. | Walid Abi-Saab Chief Medical Officer | $67k 1,434 shares | -1% | |
| 30Weak | uniQure N.V. | Matthew C Kapusta CEO, Managing Director | $1.8M 35,412 shares | -7% | |
| 18Weak | uniQure N.V. | Madhavan Balachandran director | $526k 11,685 shares | -21% | |
| 40Moderate | uniQure N.V. | Matthew C Kapusta CEO, Managing Director | $9.4M 206,100 shares | -28% | |
| 13Weak | uniQure N.V. | Jack Kaye director | $225k 5,295 shares | -17% | |
| 14Weak | uniQure N.V. | Madhavan Balachandran director | $279k 10,000 shares | -19% | |
| 41Moderate | uniQure N.V. | Jeannette Potts Chief Legal Officer | $145k 5,237 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.